Observational studyFrontiers in immunology2026
Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interpreting short-term eGFR improvement with telitacicept in IgA nephropathy.International urology and nephrology · 2026Article
- Real-world study of telitacicept in the treatment of IgA nephropathy.Frontiers in immunology · 2026Article
- The efficacy and safety of telitacicept and its combination with glucocorticoids in IgA nephropathy: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Development and validation of a routine urinalysis-based risk stratification model for IgA nephropathy in a multicenter real-world hospital population.Frontiers in nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the efficacy and safety of telitacicept combined with glucocorticoid/mycophenolate mofetil (GM) versus telitacicept in the treatment of immunoglobulin A nephropathy (IgAN). Methods: This retrospective, multicenter cohort study enrolled patients aged ≥ 18 years with biopsy-proven IgAN who were treated with telitacicept. All participants had a baseline eGFR ≥ 30 mL/min/1.73 m² and proteinuria excretion ≥ 0.75 g/day after receiving at least 1 month of optimized supportive treatment. Clinical data were collected over 9 months. Results: A total of 256 patients were enrolled in the study, with 125 patients receiving telitacicept monotherapy and 131 patients receiving telitacicept plus GM therapy. The mean age was 39.5 ± 11.6 years, and 100 patients (39.1%) were male. At 9 months, the telitacicept + GM group showed a significantly greater reduction in proteinuria (-1.32 g/day versus -0.94 g/day, Conclusion: Telitacicept + GM regimen significantly reduced proteinuria and hematuria, maintained stable renal function in patients with IgAN, with no serious adverse events occurring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.